Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

#ESMO23 Expert report on genomics profiling in the diagnosis and treatment of patients with CUP

Reporting from ESMO Congress 2023 in Madrid, Linda Mileshkin discusses the results from two trials focusing on genomics profiling in the diagnosis and treatment of patients with Cancer of Unknown Primary.

Abstracts discussed:
- LBA16 - Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP), presented by L. Mileshkin

- LBA100 - CUP-ONE Trial: A prospective double-blind validation of molecular classifiers in the diagnosis of Cancer of Unknown Primary and clinical outcomes, presented by H.S. Wasan

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.